Skip to main content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 3/2014

01.09.2014 | Review Article

Ocular Adnexal Lymphomas: Report of 2 Cases of Mantle Cell Lymphomas and Short Review of Literature

verfasst von: Kamal Kant Sahu, Preithy Uthamalingam, Santhosh Sampath, Jitender Jinagal, Ashim Das, Gaurav Prakash, Pankaj Malhotra, Subhash Chander Varma

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Mantle cell lymphoma in ocular region is a rare phenomenon which can be either primary or secondary. Most of these cases are usually diagnosed after excisional biopsy of the involved area with first visit being in the Ophthalmology OPD. We share our experience of two such cases being referred from Ophthalmology OPD. 1st case is about a 52-year-old man who came for complaints of redness of left eye with excessive lacrimation. Examination revealed congestion of left temporal bulbar conjunctiva and a small pinkish outgrowth 2 × 2 cm adherent to temporal bulbar conjunctiva. 2nd case is a 55-year-old gentlemen who presented with complaints for 8 months duration of swelling left eyelid. Excisional biopsy and histopathological examination in both the cases were done to confirm the diagnosis. CECT head and neck were done at baseline and during follow up. These cases are being presented due to the rarity and dramatic response to chemotherapy.
Literatur
1.
Zurück zum Zitat A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma (1997) The non-Hodgkin’s lymphoma classification project. Blood 89(11):3909–3918 A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma (1997) The non-Hodgkin’s lymphoma classification project. Blood 89(11):3909–3918
2.
Zurück zum Zitat Cahill M, Barnes C, Moriarty P, Daly P, Kennedy S (1999) Ocular adnexal lymphoma—comparison of MALT lymphoma with other histological types. Br J Ophthalmol 83(6):742–747PubMedCentralPubMedCrossRef Cahill M, Barnes C, Moriarty P, Daly P, Kennedy S (1999) Ocular adnexal lymphoma—comparison of MALT lymphoma with other histological types. Br J Ophthalmol 83(6):742–747PubMedCentralPubMedCrossRef
3.
Zurück zum Zitat Lanuza Garcia A, Lopez Ramos AL, Pinto Bonilla JC, Rodriguez Pereira C, Cortes Vizcaino V (2005) Management of lymphoid hyperplasia of the ocular adnexa. Arch Soc Esp Oftalmol 80(6):353–358PubMedCrossRef Lanuza Garcia A, Lopez Ramos AL, Pinto Bonilla JC, Rodriguez Pereira C, Cortes Vizcaino V (2005) Management of lymphoid hyperplasia of the ocular adnexa. Arch Soc Esp Oftalmol 80(6):353–358PubMedCrossRef
4.
Zurück zum Zitat Rasmussen P, Sjo LD, Prause JU, Ralfkiaer E, Heegaard S (2009) Mantle cell lymphoma in the orbital and adnexal region. Br J Ophthalmol 93(8):1047–1051PubMedCrossRef Rasmussen P, Sjo LD, Prause JU, Ralfkiaer E, Heegaard S (2009) Mantle cell lymphoma in the orbital and adnexal region. Br J Ophthalmol 93(8):1047–1051PubMedCrossRef
5.
Zurück zum Zitat Looi A, Gascoyne RD, Chhanabhai M, Connors JM, Rootman J, White VA (2005) Mantle cell lymphoma in the ocular adnexal region. Ophthalmology 112(1):114–119PubMedCrossRef Looi A, Gascoyne RD, Chhanabhai M, Connors JM, Rootman J, White VA (2005) Mantle cell lymphoma in the ocular adnexal region. Ophthalmology 112(1):114–119PubMedCrossRef
6.
Zurück zum Zitat Jenkins C, Rose GE, Bunce C, Wright JE, Cree IA, Plowman N et al (2000) Histological features of ocular adnexal lymphoma (REAL classification) and their association with patient morbidity and survival. Br J Ophthalmol 84(8):907–913PubMedCentralPubMedCrossRef Jenkins C, Rose GE, Bunce C, Wright JE, Cree IA, Plowman N et al (2000) Histological features of ocular adnexal lymphoma (REAL classification) and their association with patient morbidity and survival. Br J Ophthalmol 84(8):907–913PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Ferry JA, Fung CY, Zukerberg L, Lucarelli MJ, Hasserjian RP, Preffer FI et al (2007) Lymphoma of the ocular adnexa: a study of 353 cases. Am J Surg Pathol 31(2):170–184PubMedCrossRef Ferry JA, Fung CY, Zukerberg L, Lucarelli MJ, Hasserjian RP, Preffer FI et al (2007) Lymphoma of the ocular adnexa: a study of 353 cases. Am J Surg Pathol 31(2):170–184PubMedCrossRef
8.
Zurück zum Zitat Medeiros LJ, Harris NL (1989) Lymphoid infiltrates of the orbit and conjunctiva. A morphologic and immunophenotypic study of 99 cases. Am J Surg Pathol 13(6):459–471PubMedCrossRef Medeiros LJ, Harris NL (1989) Lymphoid infiltrates of the orbit and conjunctiva. A morphologic and immunophenotypic study of 99 cases. Am J Surg Pathol 13(6):459–471PubMedCrossRef
9.
Zurück zum Zitat Ferreri AJ, Govi S, Colucci A, Crocchiolo R, Modorati G (2011) Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas. Ophthalmology 118(1):24–28PubMedCrossRef Ferreri AJ, Govi S, Colucci A, Crocchiolo R, Modorati G (2011) Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas. Ophthalmology 118(1):24–28PubMedCrossRef
10.
Zurück zum Zitat Shields JA, Shields CL, Scartozzi R (2004) Survey of 1264 patients with orbital tumors and simulating lesions: the 2002 montgomery lecture, part 1. Ophthalmology 111(5):997–1008PubMedCrossRef Shields JA, Shields CL, Scartozzi R (2004) Survey of 1264 patients with orbital tumors and simulating lesions: the 2002 montgomery lecture, part 1. Ophthalmology 111(5):997–1008PubMedCrossRef
11.
Zurück zum Zitat Rootman DB, Mavrikakis I, Connors JM, Rootman J (2011) Primary, unilateral ocular adnexal lymphoma: disease progression and long-term survival. Ophthal Plast Reconstr Surg 27(6):405–409PubMedCrossRef Rootman DB, Mavrikakis I, Connors JM, Rootman J (2011) Primary, unilateral ocular adnexal lymphoma: disease progression and long-term survival. Ophthal Plast Reconstr Surg 27(6):405–409PubMedCrossRef
12.
Zurück zum Zitat Auw-Haedrich C, Coupland SE, Kapp A, Schmitt-Graff A, Buchen R, Witschel H (2001) Long term outcome of ocular adnexal lymphoma subtyped according to the REAL classification. Revised European and American lymphoma. Br J Ophthalmol 85(1):63PubMedCentralPubMedCrossRef Auw-Haedrich C, Coupland SE, Kapp A, Schmitt-Graff A, Buchen R, Witschel H (2001) Long term outcome of ocular adnexal lymphoma subtyped according to the REAL classification. Revised European and American lymphoma. Br J Ophthalmol 85(1):63PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Khanlari M, Bagheri B, Vojdani R, Mohammadianpanah M, Paydar S, Daneshbod Y (2012) Conjunctival mass as an initial presentation of mantle cell lymphoma: a case report. BMC Res Notes 5:671PubMedCentralPubMedCrossRef Khanlari M, Bagheri B, Vojdani R, Mohammadianpanah M, Paydar S, Daneshbod Y (2012) Conjunctival mass as an initial presentation of mantle cell lymphoma: a case report. BMC Res Notes 5:671PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Nakata M, Matsuno Y, Katsumata N, Takenaka T, Kobayashi Y, Narabayashi M et al (1999) Histology according to the revised European-American lymphoma classification significantly predicts the prognosis of ocular adnexal lymphoma. Leuk Lymphoma 32(5–6):533–543PubMed Nakata M, Matsuno Y, Katsumata N, Takenaka T, Kobayashi Y, Narabayashi M et al (1999) Histology according to the revised European-American lymphoma classification significantly predicts the prognosis of ocular adnexal lymphoma. Leuk Lymphoma 32(5–6):533–543PubMed
15.
Zurück zum Zitat Oh DE, Kim YD (2007) Lymphoproliferative diseases of the ocular adnexa in Korea. Arch Ophthalmol 125(12):1668–1673PubMedCrossRef Oh DE, Kim YD (2007) Lymphoproliferative diseases of the ocular adnexa in Korea. Arch Ophthalmol 125(12):1668–1673PubMedCrossRef
16.
Zurück zum Zitat Nola M, Lukenda A, Bollmann M, Kalauz M, Petrovecki M, Bollmann R (2004) Outcome and prognostic factors in ocular adnexal lymphoma. Croat Med J 45(3):328–332PubMed Nola M, Lukenda A, Bollmann M, Kalauz M, Petrovecki M, Bollmann R (2004) Outcome and prognostic factors in ocular adnexal lymphoma. Croat Med J 45(3):328–332PubMed
17.
Zurück zum Zitat McKelvie PA, McNab A, Francis IC, Fox R, O’Day J (2001) Ocular adnexal lymphoproliferative disease: a series of 73 cases. Clin Experiment Ophthalmol 29(6):387–393PubMedCrossRef McKelvie PA, McNab A, Francis IC, Fox R, O’Day J (2001) Ocular adnexal lymphoproliferative disease: a series of 73 cases. Clin Experiment Ophthalmol 29(6):387–393PubMedCrossRef
18.
Zurück zum Zitat Sharara N, Holden JT, Wojno TH, Feinberg AS, Grossniklaus HE (2003) Ocular adnexal lymphoid proliferations: clinical, histologic, flow cytometric, and molecular analysis of forty-three cases. Ophthalmology 110(6):1245–1254PubMedCrossRef Sharara N, Holden JT, Wojno TH, Feinberg AS, Grossniklaus HE (2003) Ocular adnexal lymphoid proliferations: clinical, histologic, flow cytometric, and molecular analysis of forty-three cases. Ophthalmology 110(6):1245–1254PubMedCrossRef
Metadaten
Titel
Ocular Adnexal Lymphomas: Report of 2 Cases of Mantle Cell Lymphomas and Short Review of Literature
verfasst von
Kamal Kant Sahu
Preithy Uthamalingam
Santhosh Sampath
Jitender Jinagal
Ashim Das
Gaurav Prakash
Pankaj Malhotra
Subhash Chander Varma
Publikationsdatum
01.09.2014
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 3/2014
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-014-0389-x

Weitere Artikel der Ausgabe 3/2014

Indian Journal of Hematology and Blood Transfusion 3/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.